Novel Anti-HER3 Strategy for Pancreatic Cancer
治疗胰腺癌的新型抗 HER3 策略
基本信息
- 批准号:8640116
- 负责人:
- 金额:$ 15.45万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2013
- 资助国家:美国
- 起止时间:2013-04-01 至 2015-09-30
- 项目状态:已结题
- 来源:
- 关键词:AddressAntibodiesBiological AssayBiological ProcessCancer cell lineCellsCombined Modality TherapyDataDevelopmentDrug resistanceEGFR geneEGFR inhibitionERBB2 geneERBB3 geneEpidermal Growth Factor ReceptorErlotinibEvaluationExtracellular DomainFamilyFeasibility StudiesGoalsHumanIn VitroLeadLigand BindingLigandsMalignant neoplasm of pancreasMeasurementMediatingModelingMolecularPancreasPathway interactionsPhasePhosphorylationPilot ProjectsPlayPropertyRegulationResistanceResistance developmentRoleSignal TransductionSystemTestingTherapeuticTissuesTreatment Efficacybasecancer therapyextracellulargemcitabinein vivoinhibiting antibodyinhibitor/antagonistlapatinibnovelpancreatic cancer cellspancreatic neoplasmpublic health relevancereceptorresearch clinical testingresponsetreatment strategytumortumor growth
项目摘要
DESCRIPTION (provided by applicant): The overall goal of this proposal is to develop a novel combination therapeutic strategy for treatment of pancreatic cancer using our newly developed anti-HER3 antibodies, which target both ligand-dependent and -independent pathways of HER3 activation. The central hypotheses are: (1) the extracellular domain of HER3 has at least two critical functional domains responsible for activation of HER3: one is responsible for the ligand binding and mediates HER3 activation in a ligand-dependent fashion, and another mediates and maintains HER3 activation in a ligand-independent fashion; (2) the activation of HER3 via both ligand-dependent and independent pathways are equally important for the development of resistance of pancreatic cells to EGFR and/or HER2 targeted therapies; and (3) the blockade of both pathways is required for a complete inactivation of HER3, which further would greatly enhance the efficacy of other targeted therapies such as erlotinib and lapatinib. The hypotheses were raised and have been supported by identification and characterization of a novel monoclonal anti-HER3 antibody, clone: 1A5, which primarily inhibits phosphorylation of HER3 in a ligand-independent fashion. The importance of the ligand-independent activation of HER3 was demonstrated by in vitro and in vivo anti-tumor efficacy of 1A5 alone and in combination with erlotinib or lapatinib. Furthermore, both HER3 activation pathways exist in most HER3+ pancreatic cancer cell lines we have tested, which appear to be associated with HER2 activation, and the resistance to erlotinib and lapatinib. As several anti-HER3 antibodies targeting ligand-dependent activation are under early phase clinical evaluation, our preliminary data raise a concern that only inhibition of the ligand-dependent activation of HER3 is not sufficient to override its agonistic activity to other receptors in the ERBB family, particularly, EGFR and HER2. The feasibility of this study is supported by the availability of both anti-HER3 antibodies and a novel assay system for quantitative measurement of the expression and function of the three major ERBB receptors: EGFR, HER2 and HER3, which allows us to determine the biological functions of interaction among the three receptors and the molecular mechanisms of the proposed combination therapy. Two Specific Aims will be addressed: AIM 1 will determine the role of the ligand-independent activation of HER3 in the activation of EGFR and HER2 in a panel of human pancreatic cancer cell lines and fresh pancreatic cancer tissues; and AIM 2 will determine the therapeutic efficacy of anti-HER3 in combination with erlotinib/lapatinib and gemcitabine.
描述(由申请人提供):本提案的总体目标是开发一种新型联合治疗策略,用于使用我们新开发的抗HER 3抗体治疗胰腺癌,其靶向HER 3活化的配体依赖性和非依赖性途径。核心假设是:(1)HER 3的胞外结构域具有至少两个负责HER 3活化的关键功能结构域:一个负责配体结合并以配体依赖性方式介导HER 3活化,另一个以配体非依赖性方式介导并维持HER 3活化;(2)HER 3通过配体依赖性和非依赖性途径的活化对于胰腺细胞对EGFR和/或EGFR受体的抗性的发展同样重要。或HER 2靶向治疗;和(3)阻断两种途径是HER 3完全失活所必需的,这将进一步大大增强其他靶向治疗如厄洛替尼和拉帕替尼的功效。提出了这些假设,并得到了一种新型单克隆抗HER 3抗体(克隆:1A 5)的鉴定和表征的支持,该抗体主要以配体非依赖性方式抑制HER 3磷酸化。HER 3的配体非依赖性活化的重要性通过单独的1A 5和与厄洛替尼或拉帕替尼组合的1A 5的体外和体内抗肿瘤功效证明。此外,我们测试的大多数HER 3+胰腺癌细胞系中存在两种HER 3激活途径,这似乎与HER 2激活以及对厄洛替尼和拉帕替尼的耐药性相关。由于几种靶向配体依赖性活化的抗HER 3抗体正在进行早期临床评价,我们的初步数据提出了一个问题,即仅抑制HER 3的配体依赖性活化不足以超越其对ERBB家族中其他受体(特别是EGFR和HER 2)的激动活性。本研究的可行性得到了抗HER 3抗体和用于定量测量三种主要ERBB受体(EGFR、HER 2和HER 3)的表达和功能的新型测定系统的支持,这使我们能够确定三种受体之间相互作用的生物学功能和拟议联合治疗的分子机制。将解决两个特定目的:AIM 1将确定HER 3的配体非依赖性活化在一组人胰腺癌细胞系和新鲜胰腺癌组织中EGFR和HER 2活化中的作用; AIM 2将确定抗HER 3与厄洛替尼/拉帕替尼和吉西他滨联合治疗的疗效。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
TONG ZHOU其他文献
TONG ZHOU的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('TONG ZHOU', 18)}}的其他基金
Novel Anti-HER3 Strategy for Pancreatic Cancer
治疗胰腺癌的新型抗 HER3 策略
- 批准号:
8512478 - 财政年份:2013
- 资助金额:
$ 15.45万 - 项目类别:
Death Receptor-mediated Apoptosis and Therapy Strategies in Ovarian Cancer
卵巢癌死亡受体介导的细胞凋亡和治疗策略
- 批准号:
7409970 - 财政年份:2007
- 资助金额:
$ 15.45万 - 项目类别:
Death Receptor-mediated Apoptosis and Therapy Strategies in Ovarian Cancer
卵巢癌死亡受体介导的细胞凋亡和治疗策略
- 批准号:
8018957 - 财政年份:2007
- 资助金额:
$ 15.45万 - 项目类别:
Death Receptor-mediated Apoptosis and Therapy Strategies in Ovarian Cancer
卵巢癌死亡受体介导的细胞凋亡和治疗策略
- 批准号:
7570628 - 财政年份:2007
- 资助金额:
$ 15.45万 - 项目类别:
Death Receptor-mediated Apoptosis and Therapy Strategies in Ovarian Cancer
卵巢癌死亡受体介导的细胞凋亡和治疗策略
- 批准号:
7771690 - 财政年份:2007
- 资助金额:
$ 15.45万 - 项目类别:
Death Receptor-mediated Apoptosis and Therapy Strategies in Ovarian Cancer
卵巢癌死亡受体介导的细胞凋亡和治疗策略
- 批准号:
7264774 - 财政年份:2007
- 资助金额:
$ 15.45万 - 项目类别:
Role of DDX3 in DR5-Mediated Apoptosis
DDX3 在 DR5 介导的细胞凋亡中的作用
- 批准号:
7667182 - 财政年份:2006
- 资助金额:
$ 15.45万 - 项目类别:
Role of DDX3 in DR5-Mediated Apoptosis
DDX3 在 DR5 介导的细胞凋亡中的作用
- 批准号:
7902245 - 财政年份:2006
- 资助金额:
$ 15.45万 - 项目类别:
Role of DDX3 in DR5-Mediated Apoptosis
DDX3 在 DR5 介导的细胞凋亡中的作用
- 批准号:
7908430 - 财政年份:2006
- 资助金额:
$ 15.45万 - 项目类别:
相似海外基金
University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
- 批准号:
10073243 - 财政年份:2024
- 资助金额:
$ 15.45万 - 项目类别:
Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
- 批准号:
10752129 - 财政年份:2024
- 资助金额:
$ 15.45万 - 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
- 批准号:
2339201 - 财政年份:2024
- 资助金额:
$ 15.45万 - 项目类别:
Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
- 批准号:
MR/Y008693/1 - 财政年份:2024
- 资助金额:
$ 15.45万 - 项目类别:
Research Grant
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
- 批准号:
10076445 - 财政年份:2023
- 资助金额:
$ 15.45万 - 项目类别:
Grant for R&D
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
- 批准号:
23K14783 - 财政年份:2023
- 资助金额:
$ 15.45万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
- 批准号:
23KJ0394 - 财政年份:2023
- 资助金额:
$ 15.45万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Role of antibodies in hepatitis E virus infection
抗体在戊型肝炎病毒感染中的作用
- 批准号:
10639161 - 财政年份:2023
- 资助金额:
$ 15.45万 - 项目类别:
Defining the protective or pathologic role of antibodies in Post-Ebola Syndrome
定义抗体在埃博拉后综合症中的保护或病理作用
- 批准号:
10752441 - 财政年份:2023
- 资助金额:
$ 15.45万 - 项目类别:
Human CMV monoclonal antibodies as therapeutics to inhibit virus infection and dissemination
人 CMV 单克隆抗体作为抑制病毒感染和传播的治疗药物
- 批准号:
10867639 - 财政年份:2023
- 资助金额:
$ 15.45万 - 项目类别: